These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 34915523)
1. Expression of Insulin-Like Growth Factor Type 1 Receptor Is Linked to Inflammation in Adamantinomatous Craniopharyngioma. Yang L; Li K; Li W; Wang C; Liu Y; Zhang H; Pan J; Qi S; Peng J Neuroendocrinology; 2022; 112(9):917-926. PubMed ID: 34915523 [TBL] [Abstract][Full Text] [Related]
2. Interleukin-1α leads to growth hormone deficiency in adamantinomatous craniopharyngioma by targeting pericytes: implication in pituitary fibrosis. Mao J; Qiu B; Mei F; Liu F; Feng Z; Fan J; Nie J; Huang L; Liao X; Wang Z; Zeng J; Weng Z; Zang N; Qi S; Bao Y Metabolism; 2019 Dec; 101():153998. PubMed ID: 31666193 [TBL] [Abstract][Full Text] [Related]
3. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918 [TBL] [Abstract][Full Text] [Related]
4. Interleukin‑6 induces an epithelial‑mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration. Zhou J; Zhang C; Pan J; Chen L; Qi ST Mol Med Rep; 2017 Jun; 15(6):4123-4131. PubMed ID: 28487953 [TBL] [Abstract][Full Text] [Related]
5. Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma. Chang CV; Araujo RV; Cirqueira CS; Cani CM; Matushita H; Cescato VA; Fragoso MC; Bronstein MD; Zerbini MC; Mendonca BB; Carvalho LR Neuroendocrinology; 2017; 104(2):183-193. PubMed ID: 27161333 [TBL] [Abstract][Full Text] [Related]
6. CD47 promotes the proliferation and migration of adamantinomatous craniopharyngioma cells by activating the MAPK/ERK pathway, and CD47 blockade facilitates microglia-mediated phagocytosis. Zhang H; Wang C; Fan J; Zhu Q; Feng Y; Pan J; Peng J; Shi J; Qi S; Liu Y Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12795. PubMed ID: 35156226 [TBL] [Abstract][Full Text] [Related]
7. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940 [TBL] [Abstract][Full Text] [Related]
8. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin. Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123 [TBL] [Abstract][Full Text] [Related]
9. Effects of Simvastatin on Inflammatory Response and Biological Behaviour of Adamantinomatous Craniopharyngioma. Li W; Zhang Y; Zhuang Y; Chen R; Xiong Z; Li K; Liu F; Xu H; Li D; Peng J Neuroendocrinology; 2024; 114(10):934-949. PubMed ID: 38964285 [TBL] [Abstract][Full Text] [Related]
10. Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice. Apps JR; Martinez-Barbera JP Neurosurg Focus; 2016 Dec; 41(6):E4. PubMed ID: 27903120 [TBL] [Abstract][Full Text] [Related]
11. Adamantinomatous craniopharyngioma cyst fluid can trigger inflammatory activation of microglia to damage the hypothalamic neurons by inducing the production of β-amyloid. Ainiwan Y; Chen Y; Mao C; Peng J; Chen S; Wei S; Qi S; Pan J J Neuroinflammation; 2022 May; 19(1):108. PubMed ID: 35525962 [TBL] [Abstract][Full Text] [Related]
16. Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma. Andoniadou CL; Gaston-Massuet C; Reddy R; Schneider RP; Blasco MA; Le Tissier P; Jacques TS; Pevny LH; Dattani MT; Martinez-Barbera JP Acta Neuropathol; 2012 Aug; 124(2):259-71. PubMed ID: 22349813 [TBL] [Abstract][Full Text] [Related]
17. Malignancy arising in adamantinomatous craniopharyngioma: Report of a rare case with unusual morphologic features. Das S; Sharma MC; Suri V; Sahu S; Garg A; Laythalling RK Neuropathology; 2024 Aug; 44(4):292-297. PubMed ID: 38410881 [TBL] [Abstract][Full Text] [Related]
18. Clinical features and prognosis of pediatric infradiaphragmatic craniopharyngioma relative to the tumor inflammatory response. Peng J; Yang L; Pan J; Wang C; Nie J; Liu Y; Fan J; Zhou J; Qi S Pediatr Res; 2021 Apr; 89(5):1119-1125. PubMed ID: 32559758 [TBL] [Abstract][Full Text] [Related]
19. Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Weiner HL; Wisoff JH; Rosenberg ME; Kupersmith MJ; Cohen H; Zagzag D; Shiminski-Maher T; Flamm ES; Epstein FJ; Miller DC Neurosurgery; 1994 Dec; 35(6):1001-10; discussion 1010-1. PubMed ID: 7885544 [TBL] [Abstract][Full Text] [Related]
20. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness. Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]